Dog Immune-Mediated Diseases: Complex Welfare Challenges

Immune-mediated diseases in dogs including IMHA and IMTP cause acute life-threatening illness requiring intensive treatment and long-term management to maintain quality of life.

Key Facts

Immune-mediated hemolytic anemia (IMHA) causes the immune system to destroy red blood cells
Without treatment, IMHA mortality exceeds 50% — with appropriate immunosuppression, survival reaches 70-80%
American Cocker Spaniels, Springer Spaniels, and Poodles have elevated genetic risk for IMHA
Long-term immunosuppressive therapy with prednisolone and azathioprine is required for 3-6 months minimum
Relapses are common — owners must recognize early warning signs for prompt intervention

Welfare Considerations

Immune-mediated diseases cause acute, severe welfare harm from anemia, thrombocytopenia, and organ dysfunction. Intensive initial treatment including blood transfusions and high-dose immunosuppression provides welfare through life-saving stabilization. Long-term management requires monitoring for relapse and medication side effects, balancing the welfare costs of chronic immunosuppression against the danger of undertreating disease. Genetic testing in at-risk breeds and careful vaccine scheduling in affected dogs reduce recurrence risk.

What You Can Do

Recognize warning signs of IMHA including sudden lethargy, pale gums, and rapid breathing as emergencies
Work with a veterinary internist for initial management and tapering of immunosuppressive medications
Monitor treated dogs closely for signs of relapse, particularly during medication dose reduction
Discuss risk reduction strategies with your veterinarian for dogs with prior immune-mediated disease